Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.
Copyright 2023 – Finance News Network
Source: Finance News Network
21 Jun 2022 - BluGlass Limited (ASX:BLG) President Jim Haden discusses shipping an alpha product to a customer, and the development roadmap for the company.
Read More12 May 2022 - Stealth Global Limited (ASX:SGI) CEO and Managing Director Mike Arnold discusses the company’s recently-released trading update.
Read More06 May 2020 - Acorn Capital Investment Fund Ltd. (ASX: ACQ) Head of Research and Portfolio Manager for the Consumer Discretionary, Consumer Staples and Information Technology sectors, Robert Bruce talks about the listed investment company, the fund’s composition and outlook for the next 6 months and longer term.
Read More24 Jan 2024 - Investment expert Winston Sammut discusses recent M&A activity in the property sector, analyzing BWP Trust's bid for Newmarket and Aspen's offer for Eureka Holdings. Sammut shares insights on deal rationale, pricing concerns, and potential market implications.
Read More7 July 2020 - Renergen (ASX:RLT) Managing Director, Stefano Marani talks about its high concentration of helium from Phase 1 drill results at its Virginia Gas Field in the Karoo Basin, South Africa.
Read More30 May 2022 - Fred Pye, CEO and Chairman of digital asset manager 3iQ, discusses the future of cryptocurrencies and the launch of two crypto ETFs in Australia based on Ethereum and Bitcoin.
Read More02 June 2025 - Tariff shocks, central bank inertia, defensive positioning.
Read More04 Sep 2023 - Westgold Resources (ASX:WGX) Managing Director Wayne Bramwell provides an update on the company, discussing drivers behind production results, the gold price, and plans going forward.
Read More25 Jul 2023 - BluGlass Limited (ASX:BLG) CEO Jim Haden provides an update on the company, discussing customers and market, product improvements, vertical integration and roadmap.
Read More11 Mar 2020 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.
Read More
